zonisamide has been researched along with Smoking Cessation in 1 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind, randomized, placebo-controlled pilot trial of zonisamide + varenicline versus placebo + varenicline for smoking cessation." | 9.22 | Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. ( Dunn, KE; Kim, C; Marcus, TF; Schroeder, JR; Umbricht, A; Vandrey, R, 2016) |
| "This was a double-blind, randomized, placebo-controlled pilot trial of zonisamide + varenicline versus placebo + varenicline for smoking cessation." | 5.22 | Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. ( Dunn, KE; Kim, C; Marcus, TF; Schroeder, JR; Umbricht, A; Vandrey, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dunn, KE | 1 |
| Marcus, TF | 1 |
| Kim, C | 1 |
| Schroeder, JR | 1 |
| Vandrey, R | 1 |
| Umbricht, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation[NCT01685996] | Phase 1/Phase 2 | 74 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biochemically-verified continuous smoking abstinence during weeks 7-10 of the study. (NCT01685996)
Timeframe: weeks 7-10
| Intervention | Participants (Count of Participants) |
|---|---|
| Zonisamide | 5 |
| Placebo | 6 |
Total Score from the Minnesota Nicotine Withdrawal Questionnaire (MNWQ), assessed at weekly visits. The MNWQ is a commonly-used 12-item Likert scale self-report measure of nicotine symptoms. Individual symptoms were rated from 0 (none) to 4 (severe) for each item and the Total score range was 0 - 48. Ratings were collected once weekly during study visits. (NCT01685996)
Timeframe: Past 24 hours
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening Visit | Admission Visit | Week 1 (pre-quit day) | Week 2 (pre-quit day) | Week 3 (target quit day) | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | |
| Placebo | 5.6 | 7.0 | 6.2 | 5.7 | 6.6 | 5.9 | 4.7 | 4.0 | 4.4 | 4.0 | 4.1 | 4.8 |
| Zonisamide | 4.6 | 5.1 | 5.3 | 4.8 | 4.7 | 3.8 | 3.8 | 3.4 | 3.8 | 2.7 | 3.1 | 2.6 |
1 trial available for zonisamide and Smoking Cessation
| Article | Year |
|---|---|
Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.
Topics: Adult; Humans; Isoxazoles; Nicotinic Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Var | 2016 |